Moderna shares are trading higher as traders circulate the posting of the company's new Phase 2/3 trial of pembrolizumab (Keytryuda) plus Moderna's V940 in cutaneous squamous cell carcinoma on clinicaltrials.gov on March 6. Also, Jefferies says this third study suggests more investment and confidence for the program.
Portfolio Pulse from Benzinga Newsdesk
Moderna's shares are up due to the announcement of a new Phase 2/3 trial for pembrolizumab (Keytruda) plus Moderna's V940 in cutaneous squamous cell carcinoma, as listed on clinicaltrials.gov. Jefferies' commentary on the trial suggests increased investment and confidence in the program.

March 11, 2024 | 6:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moderna's stock is experiencing an uptick following the announcement of a new Phase 2/3 trial for pembrolizumab (Keytruda) plus Moderna's V940 in cutaneous squamous cell carcinoma, indicating increased confidence and investment in the program.
The announcement of a new Phase 2/3 trial for a promising treatment in cutaneous squamous cell carcinoma, combined with positive commentary from Jefferies, suggests a strong vote of confidence in Moderna's program. This is likely to positively influence investor sentiment in the short term, as it indicates both progress in Moderna's pipeline and potential for future revenue growth.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100